## ACLX: Arcellx, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -19.4% below STRENGTH zone (4.0-10.0%); PEG unavailable fails VALUE criteria (<1.0); RSI 25 oversold (REVERSION excluded per A/B test). Stock is in no-man's land without clear edge. Caution: momentum weakening (-3.5% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($59.81)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 1
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. CAR-Therapy Keeps Analyst Confidence in Arcellx (ACLX) High Ahead of the ASH Meeting**
- Source: Finviz | 20251130T054200 | Bullish | Relevance: 97%
- Morgan Stanley reiterated a "Buy" rating for Arcellx (ACLX), maintaining high analyst confidence due to its CAR-T therapy's safety profile, potential for high MRD negativity rates, and differentiation from existing treatments. The upcoming ASH meeting data is expected to further validate anito-celâ€™s durability and efficacy, potentially driving stock upside. Despite a Q3 2025 net loss of $55.8 million, the company holds $576 million in cash, providing a runway into 2028.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-08 | Canaccord Genui | $130 | $130 | 0% |
| 2025-12-08 | Needham | $105 | $105 | 0% |
| 2025-11-18 | Wolfe Research | $0 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-08 | Canaccord Genui | main | Buy |
| 2025-12-08 | Needham | reit | Buy |
| 2025-11-18 | Wolfe Research | init | Peer Perform |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 0 ($0.00M) |
| Sells | 9 ($2.75M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 72.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 1 / 5 |

**Top Holders:**
- Gilead Sciences Inc: 11.6% (0.0%)
- T. Rowe Price Invest: 11.0% (+226.8%)
- FMR, LLC: 10.0% (-3.5%)
- Paradigm Biocapital : 8.0% (0.0%)
- Vanguard Group Inc: 6.8% (-1.0%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-3.5% 5d) with bearish MACD, trend may be turning.
2. Elevated short interest (13.9%): bears positioning against stock.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.49). Revenue growth strong at 288% YoY. Insider selling cluster ($2.7M in 90 days), potential headwind. Institutional flow bullish (1 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $4.2B |
| Beta | 0.34 |
| 52W Range | $47.86 - $94.07 |
| Short Interest | 13.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | N/A |
| Forward P/E | N/A |
| Current P/E | N/A |
| YoY Growth | N/A |
| EPS Direction | None |

### Technicals

MRS_20 deteriorating from -15.9% to -19.4% (-3.5% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 23.4pp (needs >4.0% for momentum thesis). AM_20 at -17.9% indicates price below own 20MA trend. Underperforming sector by 19.2pp, stock-specific weakness. Below SMA200 (0.97x), long-term trend not supportive. MACD histogram bearish (-2.37), momentum weakening. RSI oversold at 25, potential bounce setup.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -19.39% (CS: 0) | Weak |
| RSI_14 | 25.0 | Oversold |
| MACD Histogram | -2.37 | Bearish |
| vs SMA20 | 0.821x | Below |
| vs SMA50 | 0.814x | Below |
| vs SMA200 | 0.966x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $68.81
- **Stop Loss:** $59.81 (13.1% risk)
- **Target:** $77.81 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 111
- **Position Value:** $7,637.91
- **Portfolio %:** 7.64%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-26 (Est: $-1.06)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $-1.03 | $-0.99 | +4.1% |
| 2025Q2 | $-1.03 | $-0.94 | +8.9% |
| 2025Q1 | $-0.74 | $-1.13 | -53.0% |
| 2024Q4 | $-0.47 | $-0.87 | -83.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*